ALX ONCOLOGY HOLDINGS INC.

(ALXO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Microcap Value Index

06/24/2022 | 12:00am EDT

ALX Oncology Holdings Inc.(NasdaqGS:ALXO) added to Russell Microcap Value Index


© S&P Capital IQ 2022
All news about ALX ONCOLOGY HOLDINGS INC.
08/11First Patient Dosed in ALX Oncology's Mid-Stage Trial of Colorectal Cancer Combination ..
MT
08/11ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of E..
GL
08/11ALX Oncology Holdings Inc. Announces First Patient Dosed in Phase 2 Investigator-Sponso..
CI
08/09Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintain..
MT
08/09Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discoun..
MT
08/08ALX ONCOLOGY : Reports Second Quarter 2022 Financial Results and Provides Clinical Develop..
PU
08/08ALX ONCOLOGY : Corporate Presentation
PU
08/08ALX ONCOLOGY HOLDINGS INC Management's Discussion and Analysis of Financial Condition ..
AQ
08/08ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Mont..
CI
08/08ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Develo..
GL
More news
Analyst Recommendations on ALX ONCOLOGY HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -126 M - -
Net cash 2022 263 M - -
P/E ratio 2022 -4,72x
Yield 2022 -
Capitalization 592 M 592 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 52
Free-Float 62,5%
Chart ALX ONCOLOGY HOLDINGS INC.
Duration : Period :
ALX Oncology Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALX ONCOLOGY HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 14,52 $
Average target price 38,88 $
Spread / Average Target 168%
EPS Revisions
Managers and Directors
Jaume Pons President, Chief Executive Officer & Director
Peter S. García Chief Financial Officer
Corey S. Goodman Executive Chairman
Sophia Randolph Director & Chief Medical Officer
Michael Chang Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ALX ONCOLOGY HOLDINGS INC.-32.43%592
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968